Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to better understand the anti-inflammatory benefits of two prescription medicines that are currently used to help people with cholesterol problems.

Fish oil, from eating certain kinds of fish and from supplement pills, has been used to help control cholesterol and reduce inflammation (the body's response to injury or sickness). Lovaza® is the brand name for prescription strength fish oil pills. In this study, we will be looking at how Lovaza® works to help reduce inflammation in healthy volunteers.

Tricor® is the brand name for prescription fenofibrate pills. Fenofibrate is a prescription medicine that many doctors give to people with high triglyceride (fat in the blood) levels. In this study, we will be looking at how Tricor® works to help reduce inflammation in healthy volunteers.

Endotoxin or lipopolysaccharide (LPS) is a small part of bacteria (that is no longer living) that can cause many of the effects similar to bacterial infections in humans. However, it can be administered in very small amounts to produce a mild immune response much the same as a 'flu' like illness. Within 1 ½ -3 hours after giving LPS by vein, a response consisting of fever, chills, headache, nausea and vomiting and generalized aches and pains will occur which lasts up to 6-8 hours. In addition to the flu like symptoms, the response causes temporary changes in cholesterol, triglycerides and blood sugar. Different people respond differently to LPS. We are using LPS in this study to bring on a temporary inflammatory response in the body and to compare the responses of people who receive Lovaza® or Tricor® to the responses of people who receive a placebo (pill that does not contain medicine).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fish Oils and Adipose Inflammation Reduction

NCT02010359

Obesity

COMPLETED PHASE4

Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia

NCT01086163

Coronary Artery Disease

UNKNOWN

The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure

NCT00944229

Heart Failure

TERMINATED PHASE3

Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease

NCT01001767

HIV Infections Heart Disease

COMPLETED PHASE2

Pulmonary Vein Isolation Outcomes With Fish Oils

NCT00841451

Atrial Fibrillation

NO_LONGER_AVAILABLE

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fenofibrate (Tricor) (145 mg/day)

Participants will be given 1 fenofibrate (Tricor) 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.

Group Type EXPERIMENTAL

Fenofibrate (Tricor) tablets

Intervention Type DRUG

One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks

Placebo

Participants will be given 5 placebo pills (4 fish oil placebo and 1 fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks

Lovaza (900 mg/day)

Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.

Group Type EXPERIMENTAL

Lovaza

Intervention Type DRUG

900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.

Lovaza (3,600 mg/day)

Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.

Group Type EXPERIMENTAL

Lovaza

Intervention Type DRUG

900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fenofibrate (Tricor) tablets

One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks

Intervention Type DRUG

Placebo

Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks

Intervention Type DRUG

Lovaza

900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and non-pregnant/lactating women between the ages of 18 and 45.
* Body Mass Index (BMI) ≥18 and ≤30
* Participants who are able to give written informed consent and willing to comply with all study-related procedures.

Exclusion Criteria

* Known clinically manifest atherosclerotic cardiovascular disease, including coronary disease, cerebrovascular disease, or peripheral vascular disease
* History of diabetes mellitus
* Fasting glucose \>126mg/dL at screening
* History of a non-skin malignancy within the previous 5 years
* Renal insufficiency as defined by creatinine outside of lab defined normal range or eGFR \<60 ml/Kg/min at Screening Visit
* History of liver disease or abnormal Liver Function Tests (LFTs) (aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase, gamma-glutamyl transpeptidase (GGT) \> 1.5x upper limit of normal (ULN); bilirubin \> 2x ULN) at Screening Visit
* Men who are unwilling to limit alcohol consumption to \< 14 alcoholic drinks per week or \< 4 alcoholic drinks per occasion (American Medical Association/National Institute on Alcohol Abuse and Alcoholism (AMA / NIAAA) criteria for "at risk" usage levels) while participating in the study
* Women who are unwilling to limit alcohol consumption to \< 7 alcoholic drinks per week or \< 3 alcoholic drinks per occasion (AMA / NIAAA criteria for "at risk" usage levels) while participating in the study
* Total white blood cell count less than or equal to 3.0 THO/uL
* Hemoglobin less than 11.0 g/dL
* Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory condition or minor active infection
* Self-reported history of HIV positive
* First degree family history of premature cardiovascular disease event (father or brother if diagnosed at before 55 years of age; mother or sister if diagnosed before 65 years of age)
* Patients who have undergone any organ transplant
* Individuals who currently use tobacco products or have done so in the previous 30 days
* Treatment with aspirin, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, steroids or any immunomodulatory therapy 2 weeks prior to the Screening Visit
* Treatment with statins, fibrates or niacin 4 weeks prior to the Screening Visit.
* Current daily use of Vitamin C \> 1000 mg, Beta carotene \> 1000 IU, vitamin A \> 5000 IU, vitamin E \> 400 IU, and selenium \> 200 mcg
* Participants who are unwilling to eliminate omega-3 fatty acid (eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA)) supplements and/or fortified food, or have their usual intake of high omega-3 fish (tuna and other non-fried fish) be \> 3 to 4 servings per month as assessed by a simple screening questionnaire
* Positive urine pregnancy test result.
* Participation in another clinical trial within the previous 6 weeks prior to the Screening Visit.
* Poorly controlled blood pressure (BP \> 160/110) or on any anti-hypertensive medications.
* A diagnosis of metabolic syndrome using updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) criteria.
* Any medical condition or abnormal laboratory value that is judged clinically significant by an investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes